-
公开(公告)号：US4803156A
公开(公告)日：1989-02-07
申请号：US774829
申请日：1985-09-11
IPC分类号： C07K14/02 , C07K14/16 , G01N33/535 , G01N33/576 , G01N33/53
CPC分类号： C07K14/005 , G01N33/535 , G01N33/5761 , C12N2730/10122 , C12N2740/16222 , Y10S436/82 , Y10S436/828 , Y10S930/142 , Y10S930/221 , Y10S930/222 , Y10S930/223 , Y10S930/26 , Y10S930/31
摘要： A reagent for an ELISA determination of an antibody, the reagent comprising a peptide covalently linked to beta-lactamase. The reagent can be used in the following method to detect antibodies in a sample which involvesa. contacting the sample with protein A linked to a solid support,b. incubating the sample-protein A linked to the solid support,c. washing the incubated sample-protein A linked to the solid support,d. contacting the washed sample-protein A with the reagent,e. incubating the sample-protein A and reagent,f. washing the incubated sample-protein A-reagent, andg. determining the enzymatic activity of the resultant mass.
摘要翻译： 用于ELISA测定抗体的试剂，所述试剂包含与β-内酰胺酶共价连接的肽。 试剂可以按照以下方法用于检测涉及a的样品中的抗体。 使样品与连接到固体支持物的蛋白A接触，b。 孵育与固体支持物连接的样品蛋白A，c。 洗涤与固体支持物连接的温育样品 - 蛋白A，d。 将洗涤过的样品蛋白A与试剂接触， 孵育样品蛋白A和试剂，f。 洗涤孵育的样品蛋白A试剂，g。 测定所得物质的酶活性。
-
公开(公告)号：US4591505A
公开(公告)日：1986-05-27
申请号：US581528
申请日：1984-02-21
申请人： Alfred M. Prince
发明人： Alfred M. Prince
IPC分类号： A61K35/16 , A61L2/00 , C07K14/755
CPC分类号： A61K35/16 , A61L2/0035 , A61L2/0088 , C07K14/755
摘要： A mammalian blood plasma or plasma derivative substantially free of active hepatitis B or non-A, non-B viruses is disclosed, the plasma being characterized by the presence of factor VIII, the percent by weight of denatured factor VIII to the sum of undenatured factor VIII and denatured factor VIII being less than 50%. The plasma is sterilized by contact with a detergent, alcohol or ether, and mixtures thereof and preferably a mixture of detergent and ether, usually followed by removal of the viral sterilizing agent.
摘要翻译： 公开了基本上不含活性乙型肝炎或非A非B型病毒的哺乳动物血浆或血浆衍生物，血浆的特征在于存在因子VIII，变性因子VIII的重量百分比与未变性因子的总和 VIII和变性因子VIII小于50％。 等离子体通过与洗涤剂，醇或醚及其混合物接触而灭菌，优选通过洗涤剂和醚的混合物灭菌，通常随后除去病毒灭菌剂。
-
公开(公告)号：US4540573A
公开(公告)日：1985-09-10
申请号：US514375
申请日：1983-07-14
IPC分类号： A61K39/395 , A61K35/14 , A61K35/16 , A61K38/00 , A61K38/16 , A61K38/21 , A61K38/43 , A61L2/00 , A61K39/00 , A61K37/00 , C07G7/00 , C07C103/52
CPC分类号： A61L2/0023 , A61L2/0088 , Y10S530/829 , Y10S530/83 , Y10S530/831
摘要： A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
-
44.发明授权Vaccine for active immunization containing hepatitis B surface antigen and associated antigen 失效含有乙型肝炎表面抗原和相关抗原的主动免疫疫苗
公开(公告)号：US4164565A
公开(公告)日：1979-08-14
申请号：US831327
申请日：1977-09-07
CPC分类号： C07K14/005 , A61K39/00 , C12N2730/10122
摘要： A vaccine against viral hepatitis comprising:A. antigenic particles having a particle size in the range of 30 to 50 nanometers, said antigenic particles containing hepatitis B surface antigens;B. said antigen having less than 10 units of free antibody to hepatitis B surface antigens per 1,000 units of hepatitis B surface antigens;C. at least 5% of the particles of said vaccine in the size range of 30 to 50 nanometers containing the hepatitis B surface antigenic specificity(s) which have been termed "e-antigen";D. said hepatitis B surface antigens, including e-antigens, being present in said vaccine in an amount sufficient to produce antibodies when introduced into a host animal, the balance being a medium which is physiologically acceptable, especially to humans and primates.
摘要翻译： 一种针对病毒性肝炎的疫苗，包括：
-
45.发明授权Vaccine manufacture for active immunization containing hepatitis B surface antigen and associated antigen 失效含有乙型肝炎表面抗原和相关抗原的主动免疫疫苗生产
公开(公告)号：US4118478A
公开(公告)日：1978-10-03
申请号：US771728
申请日：1977-02-24
CPC分类号： C07K14/005 , A61K39/00 , C12N2730/10122
摘要： A process for preparing a vaccine containing unprecipitated filaments and hepatitis B Dane particle specific antigens by removal from a blood serum of other proteinaceous matter such that the serum contains less than 10% proteinaceous matter other than that associated with hepatitis B surface antigen or the filament or Dane particle specific antigen. Any virus present is inactivated, and the antigenous mass is diluted with a physiologically acceptable medium.
摘要翻译： 一种通过从其他蛋白质物质的血清中除去含有未沉淀的细丝和乙型肝炎Dane颗粒特异性抗原的疫苗的方法，使得血清含有少于10％的蛋白质物质，而不是与乙型肝炎表面抗原或细丝相关的蛋白质物质 丹参颗粒特异性抗原。 存在的任何病毒被灭活，并且用生理上可接受的培养基稀释抗原质量。
-
46.发明授权Purification of hepatitis B surface antigen by chromatography on agarose containing aminoalkyl residues 失效通过色谱法在含有氨基烷基残基的琼脂糖上纯化乙型肝炎表面抗原
公开(公告)号：US3976767A
公开(公告)日：1976-08-24
申请号：US568093
申请日：1975-04-14
申请人： A. Robert Neurath
发明人： A. Robert Neurath
CPC分类号： C07K14/005 , C12N2730/10122
摘要： A process for separating hepatitis B surface antigen from a mixture containing the same which comprises passing said mixture over an agarose gel containing terminal aminononyl or aminodecyl groups to thereby deposit on said gel said hepatitis B surface antigen while allowing other components of said mixture to pass therethrough and thereafter eluting said hepatitis B surface antigen by passing an eluting agent over said agarose gel containing hepatitis B surface antigen.
摘要翻译： 一种从含有该乙肝表面抗原的混合物中分离出乙型肝炎表面抗原的方法，该方法包括使所述混合物通过含有氨基壬基或氨基十一烷基末端的琼脂糖凝胶，从而在所述凝胶上沉积所述乙型肝炎表面抗原，同时允许所述混合物的其它组分通过 然后通过使含有乙型肝炎表面抗原的所述琼脂糖凝胶上的洗脱剂洗脱所述乙型肝炎表面抗原。
-
公开(公告)号：US20230204472A1
公开(公告)日：2023-06-29
申请号：US18171062
申请日：2023-02-17
CPC分类号： G01N1/34 , A01N1/0215 , A01N43/44 , A01P1/00 , A61L2/0088 , A61L2202/22
摘要： Described herein are methods for inactivation or reduction of pathogens, microorganisms or parasites in a sample, media, composition, utility, device, surface or organism by treatment with an alkylating compound of Structure I, followed by elimination or reduction of the residual compound of Structure I by treatment with a neutralizing agent, which eliminates or reduces the toxicity or other undesirable properties of the alkylating compound having Structure I. The neutralizing agent can be present in a treatment solution or be part of a solid-phase agent, and acts by eliminating the alkylating properties of the alkylating compound of Structure I.
-
公开(公告)号：US20220345516A1
公开(公告)日：2022-10-27
申请号：US17861471
申请日：2022-07-11
发明人： Sabyasachi Sarkar
IPC分类号： H04L67/06 , G06F16/182 , G16H10/60 , G06F16/16 , H04L67/566
摘要： A system, method, and apparatus for transferring blood donation files are disclosed. An example system includes a collection device located at a blood donation site and a collection server located in a remote location. The example collection device is configured to store blood donation information from blood donors within a blood donation batch file located at a designated directory of a memory, and store metadata related to the blood donation information to the blood donation batch file. The example collection device also transmits the blood donation batch file to a registered user device. The example collection server is configured to determine the registered user device is available via a network connection. Responsive to determining the user device is connected, the collection server acquires the blood donation batch file from the user device and aggregates the blood donation batch file with blood donation batch files received from other registered user devices.
-
公开(公告)号：US10385317B2
公开(公告)日：2019-08-20
申请号：US13483379
申请日：2012-05-30
申请人： Beth Shaz , Christopher D. Hillyer
发明人： Beth Shaz , Christopher D. Hillyer
IPC分类号： G01N33/80 , C12N5/078 , A61K35/14 , A61M1/02 , A01N1/02 , A61K35/16 , A61K35/18 , A61K35/19 , A61M1/34
摘要： The disclosure provides methods of making a red blood cell, plasma, and platelet products having a uniform dose and volume. The method comprises pooling a plurality of blood units, leukoreducing the blood and inactivating any pathogen contained therein. Plasma, RBCs, and platelets are then divided into uniform dose and volume units which have an extended shelf life.
-
公开(公告)号：US10137107B2
公开(公告)日：2018-11-27
申请号：US15512493
申请日：2015-09-18
申请人： New York Blood Center, Inc. , The United States of America, as Represented by the Secretary, Department of Health and Human Services
IPC分类号： C07D403/12 , A61K31/40 , C07D405/14 , C07D417/12 , C07D417/14 , C07D207/34 , C07C25/00 , C07C233/01 , C07D207/30 , C07D277/20 , A61P31/18
摘要： Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
-
-
-
-
-
-
-
-
-
搜索结果
222 条记录 (耗时 0.037 秒)
